FDA Approvals, In Brief
Executive Summary
Agency clears Amylin’s metreleptin, expands the use of Vertex’s Kalydeco and approves a novel formulation of indomethacin from Iroko, and Pfizer’s Prevnar 13 moves closer to getting a CDC recommendation to match its FDA approval for use in older adults.
You may also be interested in...
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
FDA Goes To Committee With Uncertainty About Metreleptin Efficacy For Partial Lipodystrophy
The Dec. 11 Endocrinologic and Metabolic Drugs Advisory Committee also will consider whether a proposed Risk Evaluation and Mitigation Strategy would address the possible risk for lymphoma and immunogenicity with Bristol-Myers Squibb/AstraZeneca’s drug.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.